Latest IMM News

A single diagnostics update sparked a breakout week, while a handful of biotech names sold off hard despite busy newsflow. Capital raisings, takeover steps and US market pushes kept healthcare in motion heading into mid-February milestones.

Immutep Limited has reached the halfway mark in enrolling patients for its global Phase III TACTI-004 trial, testing a novel immunotherapy combo in first-line non-small cell lung cancer. The trial remains on track for key milestones this year, signaling steady progress in a critical oncology space.

Small caps did the heavy lifting this week, led by two big discovery stories in resources. Funding raises and takeover moves kept attention on who can pay for the next step, not just promise it.

A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.

Immutep Limited has entered a strategic collaboration with Dr. Reddy’s, receiving a A$30 million upfront payment and potential milestones up to A$528 million, while reporting promising clinical progress across multiple cancer immunotherapy trials.

Immutep Limited reports encouraging Phase I results for IMP761, a novel LAG-3 agonist antibody targeting autoimmune diseases, demonstrating dose-dependent immunosuppression and a strong safety profile. Further trial updates are expected in early 2026.

Immutep Limited reports robust progress in its pivotal Phase III TACTI-004 trial for advanced non-small cell lung cancer, with over 120 clinical sites activated across 27 countries including the US. Patient enrolment has reached 38% of the target, keeping key milestones on track.

Immutep has struck a strategic licensing deal with Dr. Reddy’s, granting rights to commercialise its novel cancer immunotherapy Eftilagimod Alfa across key emerging markets. The agreement includes a $20 million upfront payment and potential milestones exceeding $349 million.

Immutep Limited reveals promising Phase II results from its AIPAC-003 trial, establishing 30 mg as the optimal biological dose of eftilagimod alfa combined with paclitaxel in metastatic breast cancer patients.

Immutep Limited’s Phase II EFTISARC-NEO trial reveals a novel immunotherapy combo delivering a striking 51.5% tumour response in soft tissue sarcoma patients, alongside robust immune activation signals.

Immutep Limited has received a significant A$4.6 million cash payment from the French government’s R&D tax incentive scheme, supporting its ongoing immunotherapy clinical programs.

Immutep Limited reports strong progress in its Phase III lung cancer trial with over 170 patients enrolled, alongside positive FDA feedback and a robust cash position supporting ongoing development.